BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18175948)

  • 21. Pharmacokinetics of tacrolimus in adult renal transplant recipients.
    Naik P; Madhavarapu M; Mayur P; Nayak KS; Sritharan V
    Drug Metabol Drug Interact; 2012; 27(3):151-5. PubMed ID: 23089531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients.
    Sugioka N; Kokuhu T; Okamoto M; Yoshimura N; Ito Y; Shibata N; Takada K
    J Pharm Pharmacol; 2006 Sep; 58(9):1193-200. PubMed ID: 16945177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of metal cations on plasma trough concentration of mycophenolic Acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients.
    Naito T; Mino Y; Otsuka A; Ushiyama T; Ozono S; Kagawa Y; Kawakami J
    Biol Pharm Bull; 2008 Jun; 31(6):1292-6. PubMed ID: 18520072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
    Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
    Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
    Lemaitre F; Antignac M; Fernandez C
    Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure.
    Saint-Marcoux F; Woillard JB; Jurado C; Marquet P
    Ther Drug Monit; 2013 Jun; 35(3):322-7. PubMed ID: 23666572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients.
    Sud K; Muthukumar T; Singh B; Garg SK; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):647-9. PubMed ID: 11256238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.
    Claeys T; Van Dyck M; Van Damme-Lombaerts R
    Pediatr Nephrol; 2010 Feb; 25(2):335-42. PubMed ID: 19885684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
    McAlister VC; Mahalati K; Peltekian KM; Fraser A; MacDonald AS
    Ther Drug Monit; 2002 Jun; 24(3):346-50. PubMed ID: 12021624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ushiyama T; Ozono S; Kagawa Y; Kawakami J
    Clin Biochem; 2009 May; 42(7-8):595-601. PubMed ID: 19100248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients.
    Baldan N; Rigotti P; Furian L; Margani G; Ekser B; Frison L; De Martin S; Palatini P
    Pharmacol Res; 2006 Sep; 54(3):181-5. PubMed ID: 16750634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling.
    Gustavsen MT; Midtvedt K; Vethe NT; Robertsen I; Bergan S; Åsberg A
    Ther Drug Monit; 2020 Jun; 42(3):407-414. PubMed ID: 31479042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.